Drug approval: Osimertinib as an adjuvant treatment of non-small cell lung carcinoma with EFGR mutation after complete resection

xlomafota13 shared this article with you from Inoreader Drug approval: Osimertinib as an adjuvant treatment of non-small cell lung carcinoma with EFGR mutation after complete resection Via Association française pour l'étude du cancer Bull Cancer. 2021 Oct 23:S0007-4551(21)00366-0. doi: 10.1016/j.bulcan.2021.07.007. Online ahead of print. NO ABSTRACT PMID:34702549 | DOI:10.1016/j.bulcan.2021.07.007 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.